Son, Sejin http://orcid.org/0000-0003-1523-2990
Nam, Jutaek http://orcid.org/0000-0002-0397-1449
Kim, April S.
Ahn, Jinsung
Park, Kyung Soo http://orcid.org/0000-0003-1339-5673
Phoo, May Thazin
Sherren, Brett
Zou, Weiping http://orcid.org/0000-0001-7952-3549
Lee, Soo-Hong
Farokhzad, Omid C. http://orcid.org/0000-0003-2009-270X
Shi, Jinjun
Moon, James J. http://orcid.org/0000-0003-2238-2372
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM008353)
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (T32DE007057, R01DE031951)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125087)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA271799, U01CA210152, P30CA046592)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS122536)
Article History
Received: 17 May 2021
Accepted: 26 October 2022
First Online: 23 December 2022
Competing interests
: A patent application for particles for the delivery of biomolecules has been filed, with S.S., O.C.F. and J.J.M. as inventors. O.C.F. has financial interests in Selecta Biosciences, Tarveda Therapeutics, and Seer. J.J.M. declares financial interests for board membership, as a paid consultant, for research funding, and/or as equity holder in EVOQ Therapeutics, Saros Therapeutics and Intrinsic Medicine.